|
May 9
|
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial
|
|
May 8
|
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
|
|
May 8
|
Medincell announces the suspension of listing of its shares on Euronext Paris
|
|
Mar 27
|
MedinCell to Present at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Jan 11
|
Half-Year Liquidity Contract Statement For MEDINCELL
|
|
Jan 9
|
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
|